Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification.

Häni, Levin; Kopcic, Monika; Branca, Mattia; Schütz, Alessa; Murek, Michael; Söll, Nicole; Vassella, Erik; Raabe, Andreas; Hewer, Ekkehard; Schucht, Philippe (2022). Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification. Cancers, 14(13), p. 3149. MDPI AG 10.3390/cancers14133149

[img]
Preview
Text
cancers-14-03149-v2.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

BACKGROUND

Glioblastomas with methylation of the promoter region of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene exhibit increased sensitivity to alkylating chemotherapy. Quantitative assessment of the MGMT promoter methylation status might provide additional prognostic information. The aim of our study was to determine a quantitative methylation threshold for better survival among patients with glioblastomas.

METHODS

We included consecutive patients ≥18 years treated at our department between 11/2010 and 08/2018 for a glioblastoma, IDH wildtype, undergoing quantitative MGMT promoter methylation analysis. The primary endpoint was overall survival.

RESULTS

A total of 321 patients were included. Median overall survival was 12.6 months. Kaplan-Meier and adjusted Cox regression analysis showed better survival for the groups with 16-30%, 31-60%, and 61-100% methylation. In contrast, survival in the group with 1-15% methylation was similar to those with unmethylated promoter regions. A secondary analysis confirmed this threshold.

CONCLUSIONS

Better survival is observed in patients with glioblastomas with ≥16% methylation of the MGMT promoter region than with <16% methylation. Survival with tumors with 1-15% methylation is similar to with unmethylated tumors. Above 16% methylation, we found no additional benefit with increasing methylation.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurosurgery
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Tumour Pathology
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Häni, Levin; Branca, Mattia; Schütz, Alessa Li-Na; Murek, Michael Konrad; Soell, Nicole; Vassella, Erik; Raabe, Andreas; Hewer, Ekkehard Walter and Schucht, Philippe

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

2072-6694

Publisher:

MDPI AG

Funders:

[229] Bern University Hospital = Inselspital, Universitätsspital Bern

Language:

English

Submitter:

Pubmed Import

Date Deposited:

11 Jul 2022 15:26

Last Modified:

29 Jul 2022 13:48

Publisher DOI:

10.3390/cancers14133149

PubMed ID:

35804921

Uncontrolled Keywords:

O(6)-methylguanine-DNA methyltransferase glioblastoma temozolomide

BORIS DOI:

10.48350/171215

URI:

https://boris.unibe.ch/id/eprint/171215

Actions (login required)

Edit item Edit item
Provide Feedback